pyrazoloacridine

Pyrazoloacridine is a small molecule, investigational anticancer agent and the first of a new class of rationally synthesized acridine derivatives to undergo clinical testing. It is believed to act as a dual inhibitor of DNA topoisomerase I and DNA topoisomerase II, diminishing the formation of topoisomerase-DNA adducts. This unique mechanism results in broad-spectrum antitumor activity in preclinical models, with selectivity for solid tumors, activity against hypoxic cells, and cytotoxicity in noncycling cells. Pyrazoloacridine retains full activity against multidrug-resistant tumor cells that overexpress P-glycoprotein or multidrug resistance-associated protein (MRP). It has been studied in phase I trials in adults and children and has undergone phase II trials for various cancers including lung cancer, liver cancer, breast cancer, melanoma (skin), metastatic cancer, brain/central nervous system tumors, and intraocular melanoma[1][2][6].